Literature DB >> 2893719

19F nuclear magnetic resonance analysis of the carbamate reaction of alpha-fluoro-beta-alanine (FBAL), the major catabolite of fluoropyrimidines. Application to FBAL carbamate determination in body fluids of patients treated with 5'-deoxy-5-fluorouridine.

R Martino1, M C Malet-Martino, C Vialaneix, A Lopez, M Bon.   

Abstract

alpha-Fluoro-beta-alanine (FBAL), the major catabolite of the antineoplastic fluoropyrimidines, is an amino acid which is in equilibrium with its carbamate derivative in weakly alkaline aqueous solutions containing carbonate. In both water and control biological fluids (urine, plasma) spiked with FBAL (and sodium bicarbonate, in some cases), 19F NMR was used: (i) to determine the pH range over which FBAL carbamate is present (pH greater than or equal to 7), the maximum concentration formed occurring around pH 9, (ii) to show that the amino group of FBAL interacts very slowly with a non-protein plasma component to form a compound X, unstable in acid medium. The presumed structure of X is RCONHCH2CHFCOOH, with R different from an alkyl group but still unidentified. The behavior of FBAL in urine and plasma of rats treated with FBAL or 5'-deoxy-5-fluorouridine (5'-dFUrd), a prodrug of 5-fluorouracil, and from patients treated with 5'-dFUrd was investigated. FBAL carbamate was not present in acid medium and was therefore absent in acidic human urine. However, it was found in alkaline rat urine. FBAL carbamate was found in plasma along with the compound X. The 19F NMR spectra of FBAL and derivatives are complex since alpha-fluoro-beta-ureido-propionic acid, the precursor of FBAL in the catabolic pathway of antineoplastic fluoropyrimidines, produces a signal overlapping that of FBAL carbamate, and very close to that of compound X.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893719

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

Review 1.  Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

Authors:  M C Malet-Martino; R Martino
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.

Authors:  M C Malet-Martino; P Servin; J Bernadou; J P Armand; R Martino
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

3.  Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.

Authors:  L Lemaire; M C Malet-Martino; M de Forni; R Martino; B Lasserre
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

4.  The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.

Authors:  M Arellano; M Malet-Martino; R Martino; P Gires
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.

Authors:  M Arellano; M Malet-Martino; R Martino; T Spector
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.